Qube Research & Technologies (QRT)’s Treace Medical Concepts TMCI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$653K Buy
+147,013
New +$659K ﹤0.01% 2815
2025
Q3
– Sell
-17,408
Closed -$102K – 3955
2025
Q2
$102K Buy
+17,408
New +$113K ﹤0.01% 3032
2024
Q2
– Sell
-61,997
Closed -$809K – 4713
2024
Q1
$809K Buy
61,997
+12,411
+25% +$165K ﹤0.01% 2268
2023
Q4
$632K Sell
49,586
-110,698
-69% -$1.12M ﹤0.01% 2159
2023
Q3
$2.1M Buy
160,284
+95,194
+146% +$1.74M 0.01% 1360
2023
Q2
$1.67M Buy
65,090
+27,477
+73% +$709K 0.01% 1118
2023
Q1
$947K Buy
+37,613
New +$883K ﹤0.01% 1314

Other funds holding TMCI

Qube Research & Technologies (QRT)'s TMCI Position: Q3 2026 in Review

Qube Research & Technologies (QRT) opened a new position in Treace Medical Concepts (TMCI) in Q3 2026: 147,013 shares worth $653K. The stake represents ﹤0.01% of the portfolio and ranks #2815 among its holdings. This is a return to the name: Qube Research & Technologies (QRT) previously reported a position in TMCI as recently as Q2 2025.

Qube Research & Technologies (QRT) first reported a position in TMCI in Q1 2023 and has held it in 7 quarters since. The position peaked at $2.1M in Q3 2023. 71 funds tracked by Wall St. Rank hold TMCI as of Q3 2026.

  • Qube Research & Technologies (QRT) held 147,013 shares of Treace Medical Concepts worth $653K as of Q3 2026.
  • Treace Medical Concepts was a new Qube Research & Technologies (QRT) position in Q3 2026.
  • Treace Medical Concepts made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q3 2026, its #2815 holding.
  • Qube Research & Technologies (QRT) first reported a position in Treace Medical Concepts in Q1 2023 and has held it in 7 quarters since.
  • Qube Research & Technologies (QRT)'s Treace Medical Concepts position peaked at $2.1M in Q3 2023.
  • 71 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q3 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2026, filed 13 Nov 2026.